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Henry N. Jabbour,‡ and Hilary O.D. Critchley*
From the University of Edinburgh Centre for Reproductive
Biology,* MRC Centre for Inflammation Research,† and MRC
Human Reproductive Sciences Unit,‡ The Queen’s Medical
Research Institute, Edinburgh, Scotland
The endometrium has a remarkable capacity for effi-
cient repair; however, factors involved remain unde-
fined. Premenstrual progesterone withdrawal leads to
increased prostaglandin (PG) production and local
hypoxia. Here we determined human endometrial ex-
pression of interleukin-8 (IL-8) and the roles of PGE2
and hypoxia in its regulation. Endometrial biopsy
specimens (n  51) were collected. Endometrial cells
and explants were exposed to 100 nmol/L of PGE2 or
0.5% O2. The endometrial IL-8 concentration peaked
during menstruation (P< 0.001) and had a significant
proangiogenic effect. IL-8 was increased by PGE2 and
hypoxia in secretory but not proliferative explants,
which suggests that exposure to progesterone is es-
sential. In vitro progesterone withdrawal induced sig-
nificant IL-8 up-regulation in proliferative explants
primed with progestins, but only in the presence of
hypoxia. Epithelial cells treated simultaneously with
PGE2 and hypoxia demonstrated synergistic increases
in IL-8. Inhibition of HIF-1 by short hairpin RNA abol-
ished hypoxic IL-8 induction, and inhibition of NF-B
by an adenoviral dominant negative inhibitor decreased
PGE2-induced IL-8 expression (P > 0.05). Increased
menstrual IL-8 is consistent with a role in repair. Pro-
gesterone withdrawal, hypoxia, and PGE2 regulate en-
dometrial IL-8 by acting via HIF-1 and NF-B. Hence,
progesterone withdrawal may activate two distinct
pathways to initiate endometrial repair. (Am J Pathol
2011, 178:1245–1256; DOI: 10.1016/j.ajpath.2010.11.070)
Menstruation exhibits many of the classic hallmarks of
inflammation. The withdrawal of progesterone in the late
secretory phase of the cycle triggers a cascade of in-
flammatory mediators, leading to a dramatic influx of
leukocytes into the premenstrual endometrium.1 Aftershedding, the human endometrium exhibits a remarkable
and immediate regenerative capacity. This cyclical injury
and repair is tightly controlled and, unlike resolution of
inflammation at other sites in the body, does not involve
loss of function or scarring. However, the precise local
mechanisms involved in this efficient repair have not yet
been fully elucidated. Aberrations may lead to menstrual
disorders including heavy menstrual bleeding and dys-
menorrhea. Delineation of the physiologic processes of
the endometrium could result in new therapeutic targets
for these common debilitating conditions. In addition, the
efficient endometrial model may provide an informative
comparator for other tissue sites associated with prob-
lematic scarring or persistent inflammation.
Withdrawal of progesterone occurs in the late secre-
tory endometrium as the corpus luteum regresses. Pro-
gesterone withdrawal leads to up-regulation of endo-
metrial cyclooxygenase-2 (COX-2) and subsequent
increased levels of prostaglandins (PGs), namely,
PGE2 and PGF2.
1,2 PGF2 induces myometrial con-
tractions and vasoconstriction of the endometrial spiral
arterioles. Consequently, it is believed that there is an
episode of transient hypoxia in the uppermost endo-
metrial zones. The existence of hypoxia was confirmed
in a murine model of menstruation using pimonidazole,
a marker of pO2 less than 10 mm Hg.
3 The luminal portion
of the endometrial functional layer was demonstrated to
be intensely hypoxic during simulated menstruation, with
negligible detection of pimonidazole by day 5. It was
hypothesized that PGF2 along with other endometrial
vasoconstrictors induces hypoxic conditions in the hu-
man perimenstrual endometrium to increase repair gene
expression. The role of the other major prostaglandin
present during the premenstrual phase, PGE2, is not fully
understood. It was proposed, therefore, that PGE2 may
also independently increase expression of genes respon-
sible for endometrial repair.
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AJP March 2011, Vol. 178, No. 3Interleukin-8 (IL-8, CXCL8) is a CXC chemokine, best
known for its role as a potent chemoattractant for neutro-
phils and T cells.4 In addition, it has mitogenic properties
and a key role in angiogenesis in vivo.5 These processes
are fundamental for endometrial shedding and repair.
The present study demonstrated significant changes in
IL-8 mRNA and protein expression during the menstrual
cycle, with maximal expression at menstruation. Concen-
trations of IL-8 secreted by menstrual endometrium ex-
hibited significantly greater angiogenic potential in vitro
than did concentrations secreted by mid-secretory endo-
metrium. IL-8 expression is up-regulated in endometrial
epithelial cells by hypoxic conditions and by PGE2, with a
synergistic increase observed in the presence of both
factors. An in vitro model of progesterone withdrawal also
increased IL-8 expression in human endometrial tissue,
but only with the addition of hypoxic conditions. The
presence of indomethacin, a COX enzyme inhibitor, at-
tenuated the increase in IL-8 expression in this model.
These observations suggest a role for progesterone with-
drawal in the initiation of endometrial repair and indicate
that subsequent hypoxia and PGE2 are necessary for
increased expression of IL-8, an angiogenic factor with a
putative role in the repair process.
Materials and Methods
Human Endometrial Tissue Collection and
Culture
Human endometrial biopsy specimens were collected from
women undergoing hysterectomy or investigation in the gy-
necologic outpatient setting (n  51). Ethical approval was
obtained from the Lothian Research Ethics Committee, and
written informed consent was obtained from all participants
before tissue collection. Participants were aged 31 to 52
years (median, 41 years; mean, 41 years). All women re-
ported regular menstrual cycles (duration, 21 to 35 days)
and had not taken exogenous hormones or used an intra-
uterine device during the 3 months before endometrial bi-
opsy. Women with known uterine disease such as large
myomas (3 cm) and endometriosis were excluded. Endo-
metrial biopsy specimens were collected using an endome-
trial suction curette (Pipelle; Laboratoire CCD, Paris,
France). Immediately after collection, tissue was divided
and i) placed in RNA stabilization solution (RNA Later; Am-
bion (Europe) Ltd., Warrington, UK), ii) stored at 70°C for
RNA extraction, iii) fixed in neutral buffered formalin for wax
embedding or iv) placed in PBS for in vitro culture. The
Table 1. Circulating Estradiol and Progesterone Concentrations a
Histologic stage of cycle
Age, mean,
years
Menstrual (n  8) 41
Proliferative (n  16) 42
Early secretory (n  10) 42
Mid secretory (n  11) 40
Late secretory (n  6) 42specimens were dated according to the criteria of Noyeset al6 based on histologic appearance, which was consis-
tent with the participants’ reported last menstrual period. In
addition, serum samples were collected from each woman
at biopsy to determine circulating serum progesterone and
estradiol concentrations, and were consistent for both last
menstrual period and histologic assessment. For analysis,
biopsy specimens were classified as proliferative, early se-
cretory, mid secretory, late secretory, or menstrual (Table
1). Seven women consented to undergo a second endo-
metrial biopsy, and returned for this procedure three to six
months after insertion of the levonorgestrel-releasing intra-
uterine system (LNG-IUS) for treatment of subjective report
of heavy menstrual bleeding.
In Vitro Culture of Endometrial Tissue
Endometrial biopsy specimens (secretory phase, n  7;
proliferative phase, n  3) were divided into three equal
explants and incubated for at least 16 hours on raised
platforms in 24-well plates just covered with serum-free
RPMI 1640 medium plus 50 g/ml of penicillin, 50 g/ml
of streptomycin, and 5 g/ml of gentamicin (all from
Sigma Aldrich, St. Louis, MO), and 8.4 mol/L of indo-
methacin. The next day, two explants were treated with
vehicle under normoxic conditions, 1 with 21% O2, 5%
CO2, and 37°C, and one with 100 nmol/L of PGE2. The
last explant was placed in a sealed hypoxic chamber
(Coy Laboratory Products Inc., Grass Lake, MI) set at
0.5%O2, 5% CO2, and 37°C for 24 hours.
Five endometrial biopsy specimens from the prolif-
erative phase were divided into 8 equal-sized explants
and placed on raised platforms in four wells of 2 
24-well plates. All explants were treated with 1 mol/L
of medroxyprogesterone acetate (MPA) for 24 hours.
Explants were then treated with either 1 mol/L of MPA
plus vehicle, 1 mol/L of MPA plus 8.4 mol/L of indo-
methacin (a COX enzyme inhibitor), 1 mol/L of MPA
and 1 mol/L of RU486 (a progesterone-receptor an-
tagonist) plus vehicle, or 1 mol/L of MPA and RU486
plus 8.4 mol/L of indomethacin. One plate was placed
in normoxic conditions, and the other in hypoxic con-
ditions, for 48 hours.
Culture of Endometrial Cells
Human Ishikawa endometrial adenocarcinoma cells (Euro-
pean Collection of Cell Cultures, Centre for Applied Micro-
biology, Wiltshire, UK) stably expressing the EP2 receptor
(EP2S)7 were maintained in Dulbecco modified Eagle me-
metrial Biopsy
mean (range), pmol/L P4, mean (range), nmol/L
192.25 (55–514) 3.71 (1.24–10.59)
441.18 (79–1105) 2.81 (0.97–7.1)
497.50 (289–841) 59.60 (23.2–112.91)
638.00 (242–1949) 64.30 (25.47–114.53)
318.22 (59.09–819) 8.22 (1.06–16.95)t Endo
E2,dium nutrient mixture F-12 with glutamax-1 and pyridoxine,
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(stock 500 IU/ml of penicillin and 500 g/ml of streptomy-
cin), and 200 g/ml of G418 at 37°C. Primary human endo-
metrial stromal cells were isolated from mid-secretory en-
dometrial tissue (n  3) via enzymatic digestion as
previously described,8 and were maintained in RPMI 1640
medium plus 50 g/ml of penicillin, 50 g/ml of streptomy-
cin, and 5 g/ml of gentamicin (all from Sigma Aldrich).
Approximately 4  105 EP2S or 3  105 human endo-
metrial stromal cells were seeded in 6-well plates. The
following day, cells were incubated for at least 16 hours in
serum-free culture medium containing antibiotics and 8.4
mol/L of indomethacin. Cells were then treated with
either vehicle or 100 nmol/L of PGE2 and placed at 37°C,
21% O2, and 5% CO2 for 2, 4, 8, 24, and 48 hours or
placed in hypoxic conditions (0.5%O2 and 5% CO2) in a
sealed chamber (Coy Laboratory Products Inc.) for the
same amount of time. Alternatively, EP2S cells were pre-
treated with vehicle or 5 nmol/L of echinomycin (a spe-
cific inhibitor of HIF-1 DNA binding activity).9 After 1 hour,
cells were stimulated for 6 hours with vehicle, 100 nmol/L
of PGE2 with or without 5 nmol/L of echinomycin,or hyp-
oxia with or without 5 nmol/L of echinomycin. A short-
hairpin RNA (shRNA) sequence against human HIF-1
and scrambled control oligonucleotide (TIB MOLBIOL)
were donated by Prof. T. Cramer (Charité-Universitäts-
medizin Berlin, Berlin, Germany). A 19-nucleotide se-
quence derived from human HIF-1 mRNA (U22431; bp
1470 to 1489) was used and was termed HIF-1/
shRNA.10,11 Cells were transiently transfected with lenti-
virus at a multiplicity of infection of 10 for 24 hours. Cells
were incubated in serum-free medium overnight before
treatment with 100 nmol/L of PGE2 or placed in the hy-
poxic chamber for 8 hours. Cells were washed with PBS
and harvested, and RNA or protein was extracted for
PCR or Western blot analysis. To determine the role of
NF-B in IL-8 up-regulation, EP2S cells were seeded at a
density of 1  105. The following day, cells were infected
with an adenovirus containing a dominant-negative I-B
mutant, which maintains NF-B in a cytoplasmic location,
or control adenovirus (Ad-d1703) at a total multiplicity of
infection of 50 for 8 hours. Ad-d1703 and Ad–I-B have
been described previously.12,13 Cells were serum-
starved with 8.4 mol/L of indomethacin for at least 16
hours before treatment with 100 nmol/L of PGE2 or hy-
poxic conditions for 6 hours.
Nuclear Protein Extraction
Protein was extracted from endometrial cells with a cyto-
plasmic protein lysis buffer (10 mmol/L of HEPES, pH
7.8), 10 nmol/L of KCl, 2 mmol/L of MgCl2, 1 mmol/L of
dithiothreitol, 0.1 mmol/L of EDTA, and 10% Nonident
P-40) containing protease inhibitors (Complete Mini Pro-
tease Inhibitor Cocktail; Roche Diagnostics, Ltd., Lewes,
UK). After centrifugation at 13,000 rpm for 1 minute at
4°C, the cytoplasmic fraction supernatant was removed
and stored at 80°C. The nuclear fraction was extracted
using a nuclear protein lysis buffer (50 mmol/L of HEPES
[pH 7.8], 50 nmol/L of KCl, 300 mmol/L of NaCl, 0.1
mmol/L of EDTA, 1 mmol/L of dithiothreitol, and 10%glycerol) containing protease inhibitors (Roche Diagnos-
tics, Ltd), followed by agitation for 20 minutes at 4°C and
centrifugation at 13,000 rpm for 5 minutes at 4°C. The
nuclear fraction supernatant was removed and stored at
80°C. Protein content was determined using protein
assay kits (Bio-Rad; Hemel Hempstead, UK).
HIF-1 Western Blot Analysis
For detection of HIF-1 and -actin, 10 g of nuclear pro-
tein was resuspended in a 2:1 ratio with Laemmli buffer (125
mmol/L Tris-HCl [pH 6.8], 4% SDS, 5% 2-mercaptoethanol,
20% glycerol, and 0.05% bromophenol blue) and dena-
tured for 5 minutes at 90°C. Proteins were separated on 4%
to 12% Bis-Tris gels (NuPAGE Novex; Invitrogen Corp.,
Carlsbad, CA) and transferred onto polyvinylidene difluo-
ride membrane (Millipore Corp., Billerica, MA). Membranes
were blocked overnight in 5% milk solution in Tris-buffered
saline solution and Tween 20 (50 mmol/L of Tris HCl, 150
mmol/L of NaCl, and 0.05% v/v of Tween 20). After washing
with Tris-buffered saline solution and Tween 20, the mem-
branes were incubated with mouse monoclonal anti–HIF-1
antibody (BD Biosciences, Oxford, UK) (1:250) and rabbit
polyclonal anti–-actin (Abcam, Cambridge, UK) (1:5000).
After washing, the membrane was incubated with horserad-
ish peroxidase–conjugated goat anti-mouse IgG (DAKO
Corp, Carpinteria, CA) or horseradish peroxidase–conju-
gated mouse anti-rabbit IgG (Sigma Aldrich) at 1:20,000.
The chemiluminescent horseradish perioxidase substrate
(Immobilon; Millipore Corp.) was used for immunoreactive
protein detection according to the manufacturer’s instruc-
tions.
Quantitative RT-PCR
Expression of IL-8 mRNA in endometrial tissue and
Ishikawa cells was determined using quantitative RT-PCR
(Taqman) analysis. Total RNA from cells and endometrial
biopsy specimens was extracted using a kit (RNeasy Mini
Kit; Qiagen Ltd, Sussex, UK) according to the manufac-
turer’s instructions. Samples were treated for DNA con-
tamination via DNA digestion during RNA purification.
After extraction, RNA was quantified using a spectropho-
tometer (NanoDrop 1000, version 3.7; ThermoScientific,
Wilmington, DE) and stored at 80°C. Quality of the RNA
was assessed using a bioanalyzer (Agilent 2100 Bio-
analyser System) in combination with RNA 6000 nano
chips (Agilent Technologies, Palo Alto, CA).
RNA samples were reverse transcribed using 5.5
mmol/L of MgCl2, 0.5 mmol/L each of deoxynucleotide
triphosphates, 2.5 mol/L of random hexamers, 0.4 U/lL
of RNA inhibitor, and 1.25 U/L of multiscribe reverse
transcriptase (all from PE Biosystems, Warrington, UK).
The mix was aliquoted into individual tubes, and 200 to
400 ng of RNA was added. A tube with no reverse trans-
criptase and a further tube with water were included to
control for DNA contamination. After mixing, samples
were incubated for 20 minutes at 25°C, 60 minutes at
42°C, and 5 minutes at 95°C. cDNA samples were sub-
sequently stored at 20°C.
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pared containing Taqman buffer (5.5 mmol/L of MgCl2,
200 mol/L of deoxyadenosine triphosphate, 200 mol/L
of deoxycytidine, 200 mol/L of deoxyguanosine, and
400 mol/L of deoxyuridine triphosphate), ribosomal 18S
primers and probe (Applied Biosystems, Warrington,
UK), and specific forward and reverse primers and probe
for IL-8 and EP2: IL-8 forward primer, 5=-CTGGCCGTG-
GCTCTCTTG-3=; reverse primer, 5=-TTAGCACTCCTTG-
GAAAACTG-3=; and probe, 5=-CCTTCCTGATTTCTG-
CAGCTCTGTGTGAA-3=; and EP2 forward primer,
5=-TGAAGTTGCAGGCGAGCA-3=; reverse primer, 5=-GA-
CCGCTTACCTGCAGCT-3=; and probe, 5=-CCACCCT-
GCTGCTGCTGCTTCT-3=. After mixing, 36-L aliquots
were placed in separate tubes, and 1.5 L of cDNA was
added. Into one aliquot, 1.5 L of water was added as a
no template control. Triplicate 12-L samples were
placed in a PCR plate. PCR was performed using ABI
Prism 7900 (Applied Biosystems). Data were analyzed
and processed using Sequence Detector version 2.3 (PE
Biosystems). Expression of target mRNA was normalized
to RNA loading for each sample using the 18S ribosomal
RNA as an internal standard.
IL-8 Enzyme-Linked Immunosorbent Assay
Endometrial tissue from women at each stage of the
menstrual cycle was collected in PBS (n  20), weighed,
and incubated for 24 hours on raised platforms in 1 ml of
serum-free RPMI 1640 medium with 50 g/ml of penicil-
lin, 50 g/ml of streptomycin, and 5 g/ml of gentamicin
(all from Sigma Aldrich).
IL-8 protein secretion into the culture medium by EP2S
cells and endometrial biopsy specimens after 24 hours
was quantified using an in-house enzyme-linked immu-
nosorbent assay as described previously.14 A mouse
monoclonal anti-human IL-8 capture antibody and a bio-
tinylated polyclonal goat anti-human IL-8 detection anti-
body were used (R&D Systems, Oxford, UK). Protein
concentrations in the conditioned medium were normal-
ized to tissue weight.
IL-8 Immunohistochemistry
IL-8 was immunolocalized in endometrial tissue sections
as previously described.15 In brief, slides were dewaxed
and rehydrated before antigen retrieval in 0.01mmol/L of
sodium citrate on high power in a pressure cooker for 5
minutes. Primary antibody (rabbit polyclonal, 1:100) was
added overnight at 4°C. After incubation with secondary
antibody (goat anti-rabbit, 1:200) and avidin biotin per-
oxidise complex (ABC Elite; Vector Laboratories, Peter-
borough, UK), staining was detected with liquid biamino-
benzidine (DAB kit; Zymed Laboratories, Inc., South San
Francisco, CA). Localization and intensity of immuno-
staining were evaluated blindly by two independent ob-
servers using a previously validated semiquantitative
scoring system (J.A.M.). Intensity was graded using a
three-point scale (0  no staining, 1  mild staining, and
2  strong staining). The percentage of cells stained at
each of these intensities was assessed in each cellularcompartment. A value was derived for each compartment
using the sum of these percentages after multiplication
by the intensity of staining.
Capillary Tube Formation Assay
Matrigel, 100 L (BD Biosciences, Bedford, MA), was
added in each well of a 48-well plate and allowed to polym-
erize for 1 hour at 37°C. Human umbilical vascular endo-
thelial cells were seeded at a density of 2  104 in 200 L
of EBM-2 medium (Lonza, Walkersville, MD) supplemented
with GA1000 and ascorbic acid SingleQuots (Lonza). Cells
were then treated with 250 L of culture supernatant from
menstrual and mid-secretory tissue explants incubated in
vitro for 24 hours (40 mg of tissue per milliliter of RPMI
medium) or 0.5 or 20 ng of recombinant human IL-8 (R&D
Systems) in 250 L of medium. Each dose of IL-8 was
assessed in triplicate in three separate experiments. Capil-
lary tube formations were visualized after 8 hours. Images
were captured in the same position in each well using an
inverted microscope at 5 magnification. Branch points of
the formed tubes were counted by an observer (J.A.M.)
blinded to the sample origin, and an average of the repli-
cates was determined after unblinding.
Statistical Analysis
For mRNA expression in explants and cell culture, results
are given as fold increase where relative expression of
mRNA in cells treated with PGE2 was divided by the
relative expression in vehicle-treated cells. Data are
given as mean (SEM). Significant difference was deter-
mined using one-way analysis of variance of delta cycle
threshold values using Tukey posttest analysis. For en-
dometrial biopsy specimens from across the menstrual
cycle, results are given as quantity relative to a compar-
ator, a sample of RNA from the liver. Significant differ-
ence was determined using the Kruskal-Wallis nonpara-
metric test with the Dunn multiple comparison posttest
(Instat; GraphPad Software, Inc., San Diego, CA).
Results
Expression of IL-8 mRNA and Protein in Human
Endometrium
IL-8 mRNA was present at low levels in endometrium from
the proliferative, early secretory, and mid secretory stages
of the menstrual cycle. A nonsignificant increase in IL-8
mRNA expression was observed in the late secretory
phase. By the menstrual stage, IL-8 concentrations had
increased significantly compared with endometrium from
the proliferative (P 0.01), early secretory (P 0.001), and
mid secretory (P  0.05) stages (Figure 1A. The amount of
IL-8 protein secreted from endometrial biopsy specimens
cultured in vitro for 24 hours demonstrated a similar pattern
(Figure 1B). Endometrium from the menstrual stage se-
creted significantly higher concentrations of IL-8 protein
than did tissue from the early and mid secretory phases
(P 0.05). There was no significant decrease in IL-8 protein
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calization of IL-8 demonstrated positive cytoplasmic stain-
ing in glandular epithelial, surface epithelial, stromal, and
Figure 1. IL-8 is increased in endometrium from the menstrual phase of the
cycle. A: Relative IL-8 mRNA expression in endometrium from across the
menstrual cycle. Note logarithmic scale on the y axis. B: Secreted IL-8 protein
levels by endometrial explants from different stages of the menstrual cycle
cultured in vitro for 24 hours. Immunohistochemical staining for IL-8 in
menstrual (C and D) and mid secretory (E and F) endometrium. Inset:
Negative control menstrual endometrium. Scale bar  50 m. Arrows indi-
cate perivascular cells. GE, glandular epithelial cells; St, stromal compart-
ment. G: Semiquantitative scoring of IL-8 staining in endometrial surface
epithelial (SE) cells, glandular epithelial (GE) cells, stromal compartment,
and perivascular cells. Each box represents the 25th and 75th percentiles, and
the whiskers the 10th and 90th percentiles. Horizontal lines represent the
median. M, menstrual; P, proliferative; ES, early secretory; MS, mid secretory;
LS, late secretory. *P  0.05. **P  0.01. ***P  0.001. KW, Kruskal-Wallis
statistical test.perivascular cells in endometrium from themenstrual phaseof the cycle (Figure 1, C and D). In contrast, during the mid
secretory phase of the cycle, stromal staining was negligi-
ble and glandular epithelial cells were only faintly positive
(Figure 1, E and F). Semiquantitative scoring of staining
intensity revealed that the strongest staining was in the
glandular epithelial and perivascular cells (Figure 1G). IL-8
perivascular staining was significantly increased during the
menstrual phase of the cycle when compared with the pro-
liferative (P  0.05), early secretory (P  0.01), and mid
secretory (P  0.05) stages (Figure 1G). There was a non-
significant increase in IL-8 staining in glandular epithelial
and stromal cells during the menstrual phase (Figure 1G).
Increased IL-8 Secretion by Menstrual
Compared with Mid Secretory Endometrium
Translates into Enhanced Angiogenic Activity
To assess the angiogenic potential of IL-8 produced by the
endometrium, branching of human umbilical vascular en-
dothelial cells (HUVECs) was quantified after various treat-
ments. Compared with cells treated with unconditioned me-
dium, cells treated with conditionedmedium frommenstrual
tissue incubated for 24 hours in vitro demonstrated a signif-
icant increase in HUVEC capillary branch point formation
(Figure 2A). No significant increase in angiogenesis was
observed with conditioned medium from mid secretory
phase explants. These endometrial explants are likely to
produce several angiogenic factors. To assess the contri-
bution of IL-8 alone, HUVECs were also treated with recom-
binant human IL-8. Themean (SEM; median) amount of IL-8
secreted by menstrual endometrial explants was 18.94
(7.57; 19.4) ng. Mid secretory endometrium secreted the
lowest levels of IL-8: 0.53 (0.13; 0.44) ng. Therefore, HU-
VECs were treated with control medium, 20 ng or 0.5 ng of
human recombinant IL-8. Compared with cells treated with
0.5 ng of IL-8 or control medium, treatment of HUVECs with
20 ng of IL-8 resulted in a significantly higher number of
capillary tube branch points (Figure 2B). Mid-secretory lev-
els of IL-8 had no significant effect on branch points when
compared with control medium.
IL-8 mRNA Expression Is Increased by PGE2
and Hypoxia in Secretory Endometrial Tissue
To investigate the regulation of endometrial IL-8, human endo-
metrial explants were cultured for 24 hours with vehicle, 100
nmol/L of PGE2, or hypoxic conditions. Secretory endometrium
from seven women demonstrated a nonsignificant increase in
IL-8 expression with PGE2 treatment under normoxic condi-
tions. Culture of endometrial explants under hypoxic condi-
tions significantly elevated IL-8 mRNA expression (P  0.05)
(Figure 3A). In contrast, neither treatment induced up-regula-
tion of IL-8 in endometrium from the proliferative phase (n 3)
(Figure 3B). This suggests that previous exposure to proges-
terone is essential for up-regulation of IL-8 by PGE2 and hyp-
oxia. There was no significant difference in EP2 receptor
mRNA expression in response to PGE2 or hypoxia between
explants from the proliferative and secretory phases of the
cycle (data not shown).
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Withdrawal Increase IL-8 mRNA Expression
To establish whether progesterone withdrawal induces
IL-8 mRNA expression, proliferative endometrial biopsy
specimens were divided into 8 explants (n  5). All ex-
plants were treated with MPA for 24 hours. After proges-
terone exposure, progesterone withdrawal was simulated
in four of the explants by co-treating with RU486, a pro-
gesterone-receptor antagonist. Progesterone withdrawal
under normoxic conditions did not significantly up-regu-
late IL-8 mRNA expression (Figure 4).
It was postulated that in vivo, progesterone withdrawal
in the late secretory phase induces synthesis of prosta-
glandins and constriction of spiral arterioles, resulting in
an episode of transient hypoxia. Therefore, to mimic the
in vivo condition more accurately, two endometrial ex-
plants were exposed to hypoxic conditions at simu-
lated progesterone withdrawal. Addition of hypoxic
conditions induced significant induction of IL-8 mRNA
expression 48 hours after progesterone withdrawal
Figure 2. Menstrual levels of IL-8 can up-regulate network formation in
HUVECs. A: The number of capillary tube branch points formed by HUVECs
significantly increased when treated for 8 hours with conditioned medium
(CM) from menstrual endometrial biopsy specimens cultured for 24 hours in
vitro versus control medium. No such increase was seen with conditioned
medium from mid secretory explants (n 4 or 5). B: The number of capillary
tube branch points formed by HUVECs treated with 20 ng of human recom-
binant IL-8 (M, menstrual levels) was significantly greater that those formed
when treated with control medium or 0.5 ng of IL-8 (MS, mid secretory levels)
(n  3). *P  0.05.(P  0.05) (Figure 4A).To assess the contribution of prostaglandins after
progesterone withdrawal, explants were concomitantly
treated with MPA (progestogen), RU486 (progesterone-
receptor antagonist), and indomethacin (a COX enzyme
inhibitor). Addition of indomethacin attenuated up-regu-
lation of IL-8 mRNA after progesterone withdrawal under
hypoxic conditions (Figure 4A).
To further investigate the role of progesterone and hyp-
oxia in regulating endometrial IL-8 expression, endometrial
biopsy specimens from seven women obtained before and
3 to 6 months after LNG-IUS insertion were examined. The
LNG-IUSmarkedly down-regulated theprogesterone receptor
in all components of the endometrium,16 resulting in a human
model of progesterone deficiency. At comparison of endome-
triumobtainedduring theproliferative, early secretory, andmid
secretory stages with paired samples obtained after 3- to
6-month exposure to LNG-IUS (n  7), significant up-regula-
tion of IL-8 mRNA expression was observed after LNG-IUS
exposure (P 0.05) (Figure 4B). This increase in endometrial
IL-8 after LNG-IUS insertion was also identified at the protein
level. Increased IL-8 immunohistochemical staining was visi-
ble in the decidualized stromal cells present after LNG-IUS
exposure (Figure 4, C and D). Endometrial biopsy specimens
obtained during the late secretory andmenstrual phases (n
2) demonstrated no significant change in IL-8 mRNA expres-
sion on exposure to the LNG-IUS (data not shown). This sug-
Figure 3. IL-8 mRNA up-regulation by PGE2 and hypoxia depends on cycle
stage. A: IL-8 mRNA expression in early-mid-secretory endometrium (n  7)
after in vitro culture for 24 hours under normoxic conditions with vehicle
(NV), normoxic conditions (21% O2) with 100 nmol/L PGE2 (NPGE2), or
hypoxic conditions (0.5% O2) plus vehicle (HV). B: IL-8 mRNA expression in
proliferative endometrium cultured in identical conditions (n 3). *P 0.05.
ns, not significant.
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withdrawal in vivo has no further capacity for IL-8 induction on
insertion of LNG-IUS.
PGE2 and Hypoxia Increase IL-8 mRNA and
Protein Expression in Endometrial Epithelial
Cells and Together Result in a Synergistic
Increase
To delineate the mechanisms by which PGE2 and hyp-
oxia induce IL-8 expression, an Ishikawa endometrial
epithelial cell line stably expressing the EP2 receptor was
used. This cell line was used to mimic primary endome-
trial epithelial cells, which express receptors for PGE2.
17
Cells were exposed to treatment with vehicle or 100
nmol/L of PGE2 for up to 48 hours under normoxic and
hypoxic conditions. Treatment with PGE2 under normoxic
conditions (Figure 5A) demonstrated a significant in-
crease in IL-8 mRNA expression, with maximal up-regu-
lation after 8 hours (P  0.01). Hypoxic conditions also
significantly increased IL-8 mRNA expression (Figure 5B)
but exhibited a more delayed induction, reaching maxi-
mum up-regulation after 8 to 24 hours (P  0.01). When
cells were exposed to both PGE2 and hypoxic conditions
for 24 hours (Figure 5C), there was a synergistic increase
in IL-8 mRNA expression that was significantly greater
than with treatment with PGE2 in normoxia (P  0.05) or
hypoxia (P  0.05) alone. Levels of secreted IL-8 protein
demonstrated a similar pattern, with a synergistic in-
crease in IL-8 protein secretion with PGE2 treatment un-
der hypoxic conditions (Figure 5D). In contrast, in human
endometrial stromal cells, hypoxic conditions had no sig-nificant effect on IL-8 mRNA expression or protein levels
at any time examined (data not shown). Treatment with
100 nmol/L of PGE2 resulted in a significant increase in
IL-8 mRNA expression after 48 hours (P  0.05) and a
nonsignificant increase in secreted protein levels at the
same time point (data not shown).
IL-8 Up-Regulation by PGE2 Under Normoxic
Conditions Is Inhibited by a Dominant-Negative
of NF-B
To determine the role of NF-B in up-regulation of IL-8
in the endometrium, cells were infected with a domi-
nant-negative inhibitor of NF-B (Ad–I-B) and cul-
tured for 6 hours either in the presence of vehicle or
PGE2 or under hypoxic conditions. Infection of cells
with Ad–I-B resulted in significant reduction of
PGE2-induced IL-8 mRNA expression (P  0.05) when
compared with uninfected cells or cells infected with
control Ad-d1730 (Figure 6B). Hypoxia-induced IL-8
mRNA expression was not significantly affected by
inhibition of NF-B (Figure 6C).
IL-8 Up-Regulation by Hypoxia Is Inhibited by
Echinomycin, a Pharmacologic Inhibitor of
Hypoxia-Inducible Factor-1 Binding
Echinomycin is a small molecule that inhibits the DNA
binding of hypoxia-inducible factor (HIF) to the hypoxic
response element sequence but does not affect AP-1 or
NF-B binding9 (Figure 6D–F). Cells concomitantly
Figure 4. Progesterone withdrawal results in el-
evated IL-8 mRNA expression but only under hy-
poxic conditions. A: Significant up-regulation of
IL-8 mRNA expression was observed in prolifera-
tive endometrium (n  5, five different women)
subjected to in vitro progesterone withdrawal
(Pw/d) in the presence of hypoxia (*P  0.05).
This effect was abrogated by the addition of 8.4
mol/L of indomethacin (Indo), a COX inhibitor.
B: Insertion of the LNG-IUS, with consequent local
progesterone deprivation analogous to local pro-
gesterone withdrawal, resulted in a significant in-
crease in IL-8 mRNA (P  0.05). Note logarithmic
scale on the y axis. Immunohistochemical staining
of IL-8 in mid secretory phase endometrium before
IUS insertion (C) and in endometrium from the
same woman four months after IUS insertion (D).
GE, glandular epithelial cells; St, stromal compart-
ment; dSt, decidualized stromal cells. Arrows in-
dicate perivascular cells.treated with PGE2 and 5 nmol/L of echinomycin demon-
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in IL-8 mRNA expression when compared with cells
treated with 100 nmol/L of PGE2 alone (Figure 6E). Hy-
poxia-induced IL-8 mRNA expression was abolished
when cells were concomitantly treated with 5 nmol/L of
Figure 5. IL-8 mRNA and protein expression is up-regulated by PGE2 and
hypoxic conditions (0.5% O2) in endometrial epithelial cells. A: An endome-
trial epithelial cell line (EP2S cells) treated with 100 nmol/L of PGE2 under
normoxic conditions (21% O2) showed significantly increased levels of IL-8
mRNA at 4 and 8 hours, compared with cells treated with vehicle (V) at the
same time point (n  3). B: EP2S cells under hypoxic conditions showed a
slower pattern of IL-8 mRNA induction, reaching significance after 8 hours
(n  3). C: EP2S cells treated simultaneously with PGE2 and hypoxia re-
vealed a synergistic increase in IL-8 mRNA expression after 24 hours when
compared with treatment with PGE2 in normoxia or hypoxia alone (n  3).
D: This synergistic increase was also observed when examining IL-8 secreted
protein levels in EP2S-conditioned medium from the same experiments (n 
3). *P  0.05. **P  0.01.echinomycin (P  0.05) (Figure 6F).Silencing of HIF-1 with shRNA Confirms
Involvement of HIF-1 in Upregulation of
IL-8 by Hypoxia and PGE2
HIF-1 knockdown was confirmed at Western blot anal-
ysis (see Supplemental Figure S1A at http://ajp.amjpathol.
org). There was a marked decrease in HIF-1 protein in
cells transfected with shRNA against HIF-1 before hy-
poxic incubation versus untransfected cells or those
transfected with a scrambled shRNA sequence. Speci-
ficity of the knockdown was confirmed by examination of
lamin A/C mRNA expression, which was not significantly
different with transfection of any construct (Figure S1B).
IL-8 expression was increased with PGE2 or hypoxic in-
cubation. Transfection of cells with a scrambled sequence
did not significantly change IL-8 mRNA expression. In
agreement with pharmacologic inhibition of HIF-1 binding,
the hypoxic increase in IL-8 was significantly abrogated
when HIF-1 was silenced before treatment (P  0.05)
(Figure 6H). PGE2-induced IL-8mRNA expression was non-
significantly decreased when HIF-1 was silenced, when
compared with untransfected cells.
Discussion
In the present study, significant menstrual up-regulation
of endometrial IL-8 mRNA and protein was observed. The
timing of this elevation in IL-8 expression is consistent
with the onset of endometrial repair. The data support the
hypothesis that progesterone withdrawal followed by in-
creased PGE2 and hypoxic conditions up-regulates en-
dometrial repair factor expression. Furthermore, NF-B
and HIF-1 are two transcription factors that have a role in
the induction of IL-8 for menstrual repair. Cross-talk be-
tween these factors presents a mechanism for the syner-
gistic increase in IL-8 observed when PGE2 and hypoxia
are present simultaneously, as occurs in the perimen-
strual endometrium.
Previous studies have found an increase in IL-8 mRNA
and protein expression during the late secretory phase of
the menstrual cycle.18,19 However, those studies did not
examine tissue from the menstrual phase; thus, the max-
imal increase in IL-8 during this stage was not demon-
strated. The finding of significant elevation of IL-8 protein
during menstruation is in agreement with the findings of
Jones et al,20 who reported undetectable levels of IL-8
mRNA during the menstrual cycle until a dramatic up-
regulation at menstruation. As endometrial repair has
been shown microscopically to commence on cycle day
2,21 the finding of maximal IL-8 levels during menstrua-
tion is consistent with a role in endometrial repair. A
recent study of the menstrual endometrium revealed an
increase in genes associated with extracellular matrix
biosynthesis in stromal cells from the functional layer
when compared with those from the basal layer.22 Over-
expression of these genes, which includes IL8 (4-fold
increase), suggests that fragments of the functional layer
of endometrium participate in endometrial repair.
IL-8 is a potent chemokine,4 and is reported to control
the migration and activation of leukocytes during men-
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menstrual endometrium, including monocyte chemotac-
tic protein-3, eotaxin, fractaline, and 6Ckine (chemokine
with 6 cysteines).20 By using a gene array approach and
validation with RT-PCR, Jones et al20 demonstrated that
of all of the chemokines assessed, only IL8 was signifi-
cantly increased in menstrual phase endometrium. In-
flammatory cells produce and secrete proteases, such as
matrix metalloproteinases, that have the ability to break
down the extracellular matrix.23 Therefore, the maximal
expression of IL-8 at menstruation described herein is
consistent with a role in chemotaxis and inflammatory cell
accumulation in the endometrium, key events in the initi-
ation of menstruation. In addition, leukocytes form an
essential component of the endometrial repair process.
Neutrophil depletion using the antibody RB6 8C5 mark-
edly delayed endometrial repair in the mouse model of
menstruation.24 In addition to its role in neutrophil che-
motaxis, IL-8 has important angiogenic properties5 and
induces mitogenesis of vascular smooth muscle cells.25
IL-8 interacts with two chemokine receptors, CXCR1 and
CXCR2. Both are expressed in the endometrium through-
out the menstrual cycle.26 Therefore, it was postulated
that IL-8 has a functional role in human endometrial an-
giogenesis and repair. The present study demonstrated
that menstrual phase endometrial explants have the abil-
ity to produce factors with significant angiogenic poten-
tial. In addition, the elevated levels of IL-8 present during
menstruation have increased angiogenic potential when
compared with levels secreted during the mid secretory
phase. Numerous angiogenic factors are present in the
endometrium during menstruation, including vascular en-
dothelial growth factor,3 the angiopoietins,27 and platelet-
derived growth factor.28 All likely have a role in vascular
proliferation and differentiation, enabling rapid repair ofdamaged blood vessels. An element of functional redun-
dancy of these factors is to be expected to ensure efficient
endometrial repair. Although IL-8 may not be essential for
angiogenesis during endometrial repair, the IL-8 protein
levels present during menstruation are sufficient for an ac-
tive contribution to this physiologic process.
Postmenstrual repair was traditionally considered es-
trogen-dependent. However, using scanning electron mi-
croscopy, Ludwig and Spornitz21 demonstrated that ep-
ithelial cell proliferation and migration commenced on
day 2 of the menstrual cycle and that full coverage of the
uterine lumen was achieved by day 6. Because estrogen
levels remain low throughout the menstrual phase, these
observations suggest that initiation of repair may be es-
trogen-independent. The murine model of menstruation
also supports the hypothesis that estrogen is not essen-
tial for endometrial repair.29 Ovariectomized mice were
maintained on a soy-free diet and treated with an aromatase
inhibitor to remove all estrogenic influence. When assessed
morphologically, no significant difference in the rate of en-
dometrial repair was observed in the complete absence of
estrogen. Notwithstanding the limitations of the mouse
model of simulatedmenstruation, these results support find-
ings in the human endometrium that suggest that estrogen
is not necessary for repair, although it may contribute to the
process. Therefore, it was postulated that progesterone
withdrawal rather than an increase in estradiol is the stimu-
lus for endometrial repair factor expression.
Progesterone withdrawal in vivo causes significant up-
regulation of endometrial IL-8 mRNA expression after 48
hours.1,19 However, the mechanisms by which proges-
terone withdrawal manifests this effect remain undefined.
Progesterone withdrawal during the late secretory phase
of the menstrual cycle results in up-regulation of COX-2,
Figure 6. NF-B and HIF-1 contribute to PGE2
and hypoxia-induced IL-8 mRNA expression. A:
Infection of endometrial epithelial cells (EP2S
cells) with a dominant-negative inhibitor of
NF-B (Ad–I-B) or control adenovirus (Ad-
d1703) had no significant effect on basal IL-8
levels. B: Cells infected with Ad–I-B demon-
strated significant attenuation of PGE2-induced
IL-8 mRNA expression compared with unin-
fected cells or cells infected with Ad-d1703. C:
Infection of cells with Ad–I-B had no signifi-
cant effect on the hypoxic induction of IL-8 ex-
pression. D: Treatment of cells with echinomy-
cin alone for 8 hours did not significantly alter
IL-8 mRNA expression. E: Concomitant treat-
ment of cells with 100 nmol/L of PGE2 and 5
nmol/L of echinomycin (EC), an inhibitor of
HIF-1 binding, showed a significant reduction in
IL-8 mRNA expression. F: Echinomycin treat-
ment under hypoxic conditions abolished hy-
poxia-induced IL-8 mRNA up-regulation. G:
PGE2-induced IL-8 mRNA expression in EP2S
cells was not significantly decreased by silencing
of HIF-1 by shRNA. Transfection of a scram-
bled shRNA sequence (SCR) had no significant
effect on IL-8 expression when compared with
untransfected cells (n  3). H: Hypoxic induc-
tion of IL-8 expression was significantly de-
creased when HIF-1 was silenced in cells be-
fore hypoxic incubation (n  3–5). Hypoxia,
0.5% O2; normoxia, 21% O2; V, vehicle. *P 
0.05. **P  0.01. ***P  0.001).an enzyme responsible for prostaglandin synthesis.1,30
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creases in PGF2 and other vasoconstrictors such as en-
dothelin-1 result in constriction of spiral arterioles. This
causes a transient episode of hypoxia in the functional layer
of the endometrium (Figure 7). The hypothesis that hypoxia
exists during the perimenstrual phase was derived from
classic experiments in the rhesus monkey.32 Direct obser-
vation of changes in intraocular endometrial implants dem-
onstrated vasoconstriction of the spiral arterioles and a de-
crease in blood flow. Hypoxia has also been demonstrated
in the mouse model of menstruation using pimonidazole.33
Furthermore, although some controversy remains about the
presence of hypoxia in the human endometrium,34 late se-
cretory and menstrual endometrium exhibits positive nu-
clear immunohistochemical staining for HIF-1 and CAIX,
two markers of hypoxia.35,36 Therefore, it is proposed that
hypoxia is involved in the initiation of postmenstrual repair
factor expression after progesterone withdrawal.
Herein, it has been demonstrated that PGE2 and hyp-
oxia independently up-regulate IL-8 mRNA expression in
endometrial epithelial cells and in endometrial explants
that have had previous progesterone exposure. Endome-
trial tissue from the proliferative stage, that is, with no
significant in vivo progesterone exposure, demonstrated
no such increase in IL-8 expression with PGE2 or hyp-
oxia. There was no significant difference in EP2 mRNA
expression between explants from the proliferative and
secretory phases of the cycle. In addition, previously
published data on the endometrial expression of the EP2
receptor demonstrated no significant variation across the
menstrual cycle.17 These data suggest that the variation
observed in explants from various phases of the cycle in
Figure 7. It was hypothesized that up-regulation of IL-8 in the perimenstrual
endometrium after progesterone withdrawal occurs by two pathways. Ele-
vation of COX-2 induces synthesis of PGE2 and PGF2. PGF2 is a potent
vasoconstrictor and, along with other vasoconstrictors, causes an episode of
transient hypoxia in the superficial endometrial zones. It was demonstrated
that both PGE2 and hypoxic conditions can increase endometrial IL-8 mRNA
and protein levels, with synergistic increases in IL-8 observed in the presence
of both treatments simultaneously. NF-B and HIF-1 seem to mediate
transcription of IL-8 for endometrial repair.response to PGE2 and hypoxia is not due to differinglevels of EP2 receptor expression. When proliferative ex-
plants were subjected to an in vitro model of progester-
one withdrawal using the progesterone-receptor antago-
nist mifepristone, there was no up-regulation of IL-8
under normoxic conditions. Under in vitro conditions, en-
dometrial architecture is disturbed, and up-regulation of
COX-2 and subsequent synthesis of PGF2 are unlikely to
result in vasoconstriction and local tissue hypoxia. To
overcome the limitations of the in vitro culture system,
explants were placed in a hypoxic chamber (0.5% O2) at
the time of progesterone withdrawal to more accurately
simulate the in vivo environment. The addition of hypoxic
conditions induced a significant increase in IL-8 mRNA
expression 48 hours after progesterone withdrawal,
which suggests that hypoxia is necessary for the in-
crease in endometrial repair factors at menstruation. To
delineate the contribution of prostaglandins after proges-
terone withdrawal, the COX inhibitor indomethacin was
added to the in vitro progesterone withdrawal system.
This abrogated the up-regulation of IL-8 mRNA expres-
sion, indicating that both prostaglandins and hypoxia are
required after progesterone withdrawal for up-regulation
of repair factor expression.
To determine whether a similar human model of pro-
gesterone deprivation up-regulated IL-8 expression, en-
dometrial biopsy specimens from women obtained be-
fore and after insertion of LNG-IUS were examined. This
IUS markedly down-regulates the progesterone receptor
in all endometrial compartments,16 resulting in a proges-
terone-deficient environment that simulates the in vitro
model used in the present study. The added advantage
of this in vivo human model is that the endometrial archi-
tecture remains intact, enabling the physiologic pro-
cesses of chemoattraction and vasoconstriction. Previ-
ous studies of long-term progestogen exposure have
demonstrated reduced endometrial perfusion and pro-
foundly decreased vasomotion, which may induce a rel-
ative endometrial hypoxia.37 The results demonstrated
that IL-8 mRNA expression in normal endometrium during
the proliferative, early, and mid secretory phases is low.
Paired samples obtained four to six months after LNG-
IUS insertion demonstrated significantly increased IL-8
mRNA expression in all seven women. Levels after IUS
insertion were comparable to those observed during the
normal menstrual phase. The increased IL-8 mRNA ex-
pression in this LNG-IUS human model of progesterone
withdrawal is comparable to the finding of significantly
elevated IL-8 mRNA expression in endometrial samples
from women obtained 48 hours after withdrawal of vagi-
nal progesterone administration compared with mid se-
cretory control endometrium.1
After progesterone withdrawal during the late secre-
tory phase, both PGE2 and hypoxia are present in the
luminal portion of the endometrium. Therefore, the effect
of both PGE2 plus hypoxic conditions on IL-8 expression
in endometrial cells was examined. An Ishikawa endome-
trial epithelial cell line was used for these studies be-
cause primary human glandular endometrial epithelial
cells have a limited capacity to proliferate in culture.
Treatment with PGE2 and hypoxia induced a synergistic
increase in IL-8 mRNA and protein compared with either
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the two pathways of IL-8 stimulation. Another endometrial
proangiogenic factor, CYR61, has a similar regulation
pattern.38 Endometrial cells treated with hypoxia and
PGE2 demonstrated a synergistic increase in CYR61
mRNA and protein levels. Mechanistic studies have de-
scribed CYR61-mediated induction of IL-8 receptors
CXCR1 and CXCR2.39 Hence, there is evidence that hyp-
oxia and PGE2 initiate a perimenstrual angiogenic and
tissue repair response by activation of CYR61- and IL-8–
mediated signaling.
HIF-1 and NF-B are two nuclear transcription factors
present in the endometrium during the perimenstrual
phase.35,40 The hypoxic response element and the
NF-B binding site have both previously been identified
in the IL-8 promoter.41,42 Both HIF-1 and NF-B up-reg-
ulate IL-8 mRNA expression in cells from other tissue
sites in the body.41,43,44 An adenoviral dominant-nega-
tive inhibitor of NF-B (Ad–I-B) maintains NF-B in a
cytoplasmic location, preventing transcription of its target
genes. On infection of endometrial epithelial cells with
Ad–I-B, there was a significant decrease in PGE2-me-
diated IL-8 mRNA up-regulation. Concomitant treatment
with hypoxia and echinomycin revealed a significant re-
duction in hypoxia-mediated IL-8 mRNA expression.
These results suggest that PGE2-mediated IL-8 up-regu-
lation is NF-B–dependent and that hypoxia-mediated
IL-8 up-regulation is HIF-1–mediated. Echinomycin also
reduces c-Myc and AP-1 binding by 30% and 50%, re-
spectively,45 and these transcription factors may also
contribute to the decrease in IL-8 production. However,
specific inhibition of HIF-1 with shRNA also demon-
strated a significant reduction in hypoxia-mediated IL-8
expression. This supports the presence of an interaction
between NF-kB and HIF-1 to regulate IL-8 expression.
There is mounting evidence for cross-talk between NF-B
and HIF-1 in other tissue sites.46–49 Therefore, the pres-
ence of both of these transcription factors and possible
cross-talk between them may explain the synergistic up-
regulation of IL-8 mRNA observed in endometrial cells
exposed to PGE2 and hypoxic conditions simultaneously.
Aberrations in endometrial repair factor expression
may lead to prolonged heavy menstrual bleeding. In
women with menstrual blood loss in excess of 90 ml the
PGF2-PGE2 ratio is significantly decreased
50 and pros-
taglandin F2 receptor expression is also decreased.
51
Excessive PGE2 production at the expense of PGF2may
result in less constriction of the spiral arterioles and an
absent or decreased perimenstrual hypoxic insult. If en-
dometrial repair factor expression depends on the inter-
action between PGE2 and hypoxia-induced pathways, it
can be speculated that endometrial repair processes
may be defective in these women as a result of an altered
hypoxic episode.
In summary, IL-8 mRNA and protein are increased in
the human endometrium at menstruation. The present
data support the hypothesis that progesterone with-
drawal, followed by increased PGE2 and hypoxic condi-
tions, up-regulates endometrial repair factor expression.
Endometrial IL-8 mRNA up-regulation may be mediated
by NF-B and HIF-1. Cross-talk between these two tran-scription factors presents a mechanism for the synergis-
tic increases in IL-8 observed in endometrial cells when
PGE2 and hypoxia are present together. Further studies
are required to determine whether hypoxic conditions
and subsequent repair factor expression are aberrant in
women with heavy menstrual bleeding.
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